Nature Reviews Drug Discovery contents December 2015 Volume 14 Number 12 pp 805-877

If you are unable to see the message below, click here to view.

Advertisement
Nature Reviews Drug Discovery Special on targeting the IL-17 pathway in inflammatory disease   POSTER - Targeting the IL-17 pathway in inflammatory disease   ANIMATION - Psoriasis and beyond: targeting the IL-17 pathway   Animation and Poster produced with support from Eli Lilly and Company
TABLE OF CONTENTS
December 2015 Volume 14 Number 12		Advertisement
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Complement, a target for therapy in inflammatory and degenerative diseases B. Paul Morgan & Claire L. Harris	The discussion on Alzheimer’s Disease continues  Nature Neuroscience presents a community forum on Alzheimer's Disease (AD) research. ACCESS NOW to view videos of our panel event at SfN 2015, read related articles for free, and discuss critical issues facing AD research today. Produced with support from Eli Lilly and Company and vTv Therapeutics
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Focus on Telomeres In this special Focus on Telomeres, Nature Structural & Molecular Biology explores how the length of chromosome ends is regulated to limit cell proliferation, and how this mechanism is compromised in human disease or is circumvented by tumor cells, thus permitting unregulated cell growth.  Access the Focus free online. Produced with support from Geron Corporation and Janssen Oncology.
Comment: Industry-academia collaborations for biomarkers Khusru Asadullah, Andreas Busch, Matthias Gottwald, Petra Reinke & Lilla Landeck p805 | doi:10.1038/nrd4727 Several types of collaboration are being pursued to identify, validate and apply new biomarkers. Here, we highlight examples of such initiatives and discuss the challenges, approaches to address these challenges and key factors for success. Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
The phenotypic screening pendulum swings Asher Mullard p807 | doi:10.1038/nrd4783 Industry and academic scientists are working together to figure out when and how best to use phenotypic screening in drug discovery. PDF
Pioneering biased ligand offers efficacy with reduced on-target toxicity Katie Kingwell p809 | doi:10.1038/nrd4784 Clinical success with Trevena's 'biased' G protein-coupled receptor ligand highlights the potential of exploring the nuances of receptor pharmacology. PDF
NEWS IN BRIEF Regulators approve the first cancer-killing virus Asher Mullard p811 | doi:10.1038/nrd4805 PDF
Priority review voucher pitfalls Asher Mullard p811 | doi:10.1038/nrd4806 PDF
FDA approves anticoagulant antidote Asher Mullard p811 | doi:10.1038/nrd4807 PDF
BIOBUSINESS BRIEFS Market watch: Where is personalized medicine in industry heading? Christopher-Paul Milne, Joshua P. Cohen & Ranjana Chakravarthy p812 | doi:10.1038/nrd4759 PDF
BIOBUSINESS BRIEFS Patent watch: Australia's highest court decides isolated nucleic acids are not patent eligible Leigh Guerin & Mark Wickham p813 | doi:10.1038/nrd4790 PDF
AN AUDIENCE WITH Karen Midthun p814 | doi:10.1038/nrd4792 Karen Midthun, outgoing Director of the FDA's Center for Biologics Evaluation and Research, reflects on 22 years at the agency. PDF
FROM THE ANALYST'S COUCH Two decades of new drug development for central nervous system disorders Aaron S. Kesselheim, Thomas J. Hwang & Jessica M. Franklin p815 | doi:10.1038/nrd4793 This article analyses the characteristics of the pipeline for experimental drugs for central nervous system disorders and how they have fared in the clinical phases prior to FDA approval over the past two decades. PDF
RESEARCH HIGHLIGHTS Top Lead identification: Shedding light on dark chemical matter p817 | doi:10.1038/nrd4787 PDF Pain: TLR5 opens the door to neuropathic-pain treatment p818 | doi:10.1038/nrd4785 PDF Cancer: Xenograft encyclopaedia identifies drug combination opportunities p818 | doi:10.1038/nrd4788 PDF Immunotherapy: Remote control CARs p819 | doi:10.1038/nrd4789 PDF Infectious disease: Glutamine analogue reverses cerebral malaria p820 | doi:10.1038/nrd4786 PDF IN BRIEF Cancer: Novel IDH1 mutant inhibitors identified | Inflammatory disorders: Blocking periodontal bone loss | Ophthalmology: Dual VEGF receptor antagonist reverses retinal disease | Drug screening: Identifying novel protein kinase inhibitors PDF Drug Discovery JOBS of the week Postdoctoral Position in Scaffold Design & Drug / gene Delivery for Neural Tissue Engineering Research Nanyang Technological University (NTU) Call for New Group Leaders Institute of Molecular & Cellular Pharmacology (IPMC) Postdoctoral Position in Neuroscience and Nanotechnology Northwestern University Northwestern University Call for new group leaders The Institute of Molecular & Cellular Pharmacology (IPMC) Lab Head, Immunology and Biochemistry Novartis Institutes for BioMedical Research More Science jobs from Drug Discovery EVENT International Conference on Dermal Drug Delivery by Nanocarriers 14.03.16 Berlin, Germany More science events from
Advertisement
Renova Life Inc. specializes in transgenic rabbits and guinea pigs production via conventional DNA or RNA microinjection, engaged in developing bioreactor systems and/or novel disease models with TELAN and CRISPR-Cas9 editing technologies. For more information, please see http://www.renovalife.com/transgenic_rabbits.php http://www.renovalife.com/gene%20editing.php
PERSPECTIVES		Top
OPINION Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? David Brown p821 | doi:10.1038/nrd4675 Drug resistance is threatening to sideline the currently available antibiotics, and new antibiotics are unlikely to become available before the current arsenal becomes ineffective. Brown proposes the use of approved drugs or neutraceuticals as antibiotic resistance breakers — compounds that could be administered alongside current antibiotics to prolong their useful lifespan — to bridge the gap. Abstract | Full Text | PDF
OPINION Pioneering government-sponsored drug repositioning collaborations: progress and learning Donald E. Frail, Madeleine Brady, K. Jane Escott, Alison Holt, Hitesh J. Sanganee, Menelas N. Pangalos, Chris Watkins & Craig D. Wegner p833 | doi:10.1038/nrd4707 A new model for translational research and drug repositioning has recently been established based on three-way partnerships between public funders, the pharmaceutical industry and academic investigators. This article discusses the progress with two pioneering initiatives — one involving the UK Medical Research Council and one involving the US National Center for Advancing Translational Sciences — and the unique requirements and challenges for this model. Abstract | Full Text | PDF | Supplementary information
REVIEWS		Top
Clinical experiences with systemically administered siRNA-based therapeutics in cancer Jonathan E. Zuckerman & Mark E. Davis p843 | doi:10.1038/nrd4685 Several Phase I trials evaluating systemically administered siRNA-based therapeutics for cancer have recently been completed. Here, Zuckerman and Davis critically assess these studies and discuss key lessons learnt and implications for the future development of siRNA-based therapeutics and clinical trial design. Abstract | Full Text | PDF
Complement, a target for therapy in inflammatory and degenerative diseases B. Paul Morgan & Claire L. Harris p857 | doi:10.1038/nrd4657 The complement cascade, a key regulator of innate immunity, is a rich source of potential therapeutic targets for diseases including autoimmune, inflammatory and degenerative disorders. Morgan and Harris discuss the progress made in modulating the complement system and the existing challenges, including dosing, localization of the drug to the target and how to interfere with protein–protein interactions. Abstract | Full Text | PDF
Corrigendum: Cancer drug developers counteract kinase gatekeeper mutations Asher Mullard p877 | doi:10.1038/nrd4797 Full Text | PDF
Corrigendum: Do you want chips with that? Asher Mullard p877 | doi:10.1038/nrd4808 Full Text | PDF
Advertisement
Nature Outlook Cannabis Cannabis is undergoing a resurgence of botanical and biomedical interest, spurred by claims of its therapeutic benefits. Yet research into these claims lags behind the legislation that allows medical marijuana use. Scientists are racing to fill this cannabis knowledge gap.  Access the Outlook free online  Produced with support from: GW Pharmaceuticals Plc.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.